Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

FDA clearance of 1,25-Dihydroxy Vitamin D assay

24th Jun 2013 07:00

RNS Number : 6495H
Immunodiagnostic Systems Hldgs PLC
24 June 2013
 



24 June 2013

 

Immunodiagnostic Systems Holdings plc

FDA clearance of automated 1,25-Dihydroxy Vitamin D assay on the IDS-iSYS system

 

IDS ("IDS" or '"the Company") is pleased to announce that it has received USA FDA (Food and Drug Administration) clearance for its 1,25-Dihyroxy Vitamin D assay for use on the IDS-iSYS system.

 

The 1,25-Dihydroxy Vitamin D test is used to measure 1,25-Dihydroxy vitamin D deficiency which is associated with renal disease and is also used in the diagnosis of disorders in the metabolism of 25 hydroxyvitamin D and phosphate.

 

The IDS-iSYS 1,25-Dihydroxy Vitamin D kit is a complete test system with the proven immunocapsule extraction and automated chemiluminescence immunoassay. This enables the quantitative determination of 1,25-Dihydroxy vitamin D in human serum and plasma in a single working day providing significant efficiency benefits in vitamin D testing for laboratories.

 

IDS launched the first ever automated assay for 1,25-Dihydroxy vitamin D in Europe in April 2012 and the FDA approval now allows the Company to market the assay in the United States. It is estimated that 1,25-Dihyroxy vitamin D tests represent 15% of the total annual vitamin D testing market, which is $135M for the US (Source: Kalorama Worldwide (2012); Mkt for IVD Tests 8th Edition).

 

Patrik Dahlen, CEO of IDS, said:

 

"We are delighted to receive FDA clearance for our automated 1,25-Dihydroxy Vitamin D assay. This will allow us to market this assay in the United States and offer our laboratory customers the significant efficiency benefits from using this automated assay compared to more traditional testing methods".

 

For further information:

 

Immunodiagnostic Systems Holdings plc

Tel : +44 (0)191 5190660

Patrik Dahlen, Chief Executive Officer

Chris Yates, Finance Director

Peel Hunt LLP

Tel : +44 (0)207 418 8900

James Steel

Dr Vijay Barathan

FTI Consulting

Tel : +44 (0)207 831 3113

Ben Atwell

Simon Conway

Mo Noonan

 

About Immunodiagnostic Systems Holdings PLC

The Group operates in the in-vitro diagnostics ("IVD") market by designing, manufacturing and selling immunoassay kits as well as its automated analyser, the IDS-iSYS System. The IDS product range is used to measure or detect particular substances within a sample, thus aiding the diagnosis or monitoring of a disease or providing information for research studies.

http://www.idsplc.com

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCFMGZVFFVGFZM

Related Shares:

IDH.L
FTSE 100 Latest
Value8,809.74
Change53.53